Maca for Sexual Function

Verdict: Maca: weak, preliminary evidence for libido

Several small randomized trials suggest maca may modestly improve sexual desire and self-reported sexual function, but the evidence is preliminary and low-quality, and "maca" supplements marketed for sex have repeatedly been found adulterated with hidden prescription erectile-dysfunction drugs.

B 🟡 B Preliminary Evidence Published with Warning

🔬Why this grade7-layer evidence engine

Six human trials feed this grade. Small double-blind RCTs reported improved sexual desire in healthy men (PMID 12472620), better remission of antidepressant-induced sexual dysfunction in women (PMID 18801111; PMID 25954318), reduced sexual complaints in postmenopausal women (PMID 18784609), and improved IIEF/AMS scores in men with late-onset hypogonadism (PMID 36593713). Notably, none of these effects tracked with testosterone or estrogen, so the mechanism is unclear.

The signal stays preliminary because samples are tiny (n=14 to 80) and follow-up is short. A 2010 systematic review (PMID 20691074) found only four eligible RCTs and concluded the trials were too few, too small, and too methodologically weak for firm conclusions. That ceiling is why this lands at a 'preliminary evidence' tier rather than higher.

Regulators and clinics add caution, not support. The FDA warned consumers against 'Peru Maca' after finding it spiked with hidden sildenafil (the active drug in Viagra), a serious risk with nitrate medications. EU/EFSA-side bodies flag possible genotoxicity concerns, and Harvard, Cleveland Clinic, and urology/sexual-medicine societies stop at cautious, non-endorsing language. Buy from reputable sources and treat aggressive 'sexual enhancement' claims as a red flag for adulteration.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.62
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
B · Published with Warning
Confidence
75%
Broadly consistent
Evidence level
E3
Single high-quality meta-analysis

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.40
L3 MechanismPlausibility
0.65
L11 AI re-checkIndependent read
0.65
L1 ExamineGlobal benchmark
0.70
L2 PubMedPrimary literature
0.75
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.622
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高階證據未達主導 (0 positive vs 1 negative),由 raw_score 決定
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (6)L2 · primary research & systematic reviews

Maca (L. meyenii) for improving sexual function: a systematic review
PMID: 20691074 2010 系統性回顧
Finding: 4 RCTs met inclusion criteria; 2 showed positive effects in menopausal women and adult men; 1 no effect in cyclists; 1 positive for ED. Concluded 'limited evidence' — total trials, sample size, and methodological quality too low for firm conclusions.
Academic
View on PubMed
Effect of Lepidium meyenii (MACA) on sexual desire and its absent relationship with serum testosterone levels in adult healthy men
PMID: 12472620 2002 RCT (double-blind)
Finding: Improvement in sexual desire observed from week 8 onward; effect independent of testosterone or estradiol changes (p=NS for hormones).
🟠 Limited quality Academic
View on PubMed
A double-blind, randomized, pilot dose-finding study of maca root (L. meyenii) for the management of SSRI-induced sexual dysfunction
PMID: 18801111 2008 RCT (double-blind) n = 20
Finding: 3.0 g/day significantly improved ASEX (p=0.028) and MGH-SFQ (p=0.017); 1.5 g/day did not. Both doses improved libido (p<0.05). Small n=20 pilot.
🟠 Limited quality Government
View on PubMed
A double-blind placebo-controlled trial of maca root as treatment for antidepressant-induced sexual dysfunction in women
PMID: 25954318 2015 RCT (double-blind) n = 42
Finding: Maca group had higher remission rates on ASEX and MGH-SFQ vs placebo; strongest effect in postmenopausal subgroup. No hormone-level changes attributed.
Government
View on PubMed
Beneficial effects of Lepidium meyenii (Maca) on psychological symptoms and measures of sexual dysfunction in postmenopausal women are not related to estrogen or androgen content
PMID: 18784609 2008 RCT (double-blind) n = 14
Finding: Maca significantly reduced psychological symptoms (anxiety, depression) and sexual dysfunction vs placebo (p<0.05); no difference in serum estradiol, FSH, LH, SHBG (p>0.05).
🟠 Limited quality Government
View on PubMed
Efficacy and Safety of Maca (Lepidium meyenii) in Patients with Symptoms of Late-Onset Hypogonadism: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
PMID: 36593713 2023 RCT (double-blind) n = 80
Finding: Maca significantly improved AMS, IIEF, and IPSS scores vs placebo (p<0.05); ADAM positive rate significantly decreased (p<0.0001). Testosterone levels not elevated.
Government
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
FDA advised consumers not to purchase or use Peru Maca. FDA laboratory analysis confirmed that Peru Maca contains sildenafil, the active ingredient in the FDA-approved prescription drug Viagra, used to treat erectile dysfunction. source↗
L4b EU EFSA
Cautious
L4d TW TFDA / 衛福部
Cautious
「Maca猛戈膠囊」(紳○實業有限公司製造)含有西地那非(Sildenafil citrate,即威而鋼成分)及他達拉非(Tadalafil,即犀利士成分),副作用包括降低血壓、頭痛、嘔吐、頭暈及暫時性視力模糊,並可能和某些藥物產生交互作用,衛生署呼籲消費者不要購買及服用誇大療效之產品。 source↗
L5c Cleveland Clinic
Cautious
L5d Harvard Health
Cautious
L5e Specialty Society (condition-mapped)
Cautious
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬6 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-sexual-function-INT-maca-001 繁體中文版 →